Synopsis
Synopsis
0
VMF
0
Canada
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
2. (2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic Acid
3. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
4. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
5. Cetirizine (r)-form Dihydrochloride
6. Levocetirizine
7. Levocetirizine Hydrochloride
8. Levocetrizine
9. Ucb-28556
10. Xusal
11. Xyzal
1. 130018-87-0
2. Xyzal
3. Xusal
4. (r)-cetirizine Dihydrochloride
5. Levocetirizine Hcl
6. Levocetirizine Dihydrochloride [usan]
7. Cetirizine (r)-form Dihydrochloride
8. Ucb-28556
9. Sod6a38aga
10. Ucb 28556
11. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
12. (r)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
13. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
14. Nsc-758898
15. Levocetirizine Hydrochloride (jan)
16. (-)-cetirizine Dihydrochloride
17. 2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid;dihydrochloride
18. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid Dihydrochloride
19. Levocetirizine (dihydrochloride)
20. Levocetirizine Hydrochloride [jan]
21. Levocetirizine 2hcl
22. Unii-sod6a38aga
23. Levocetirizine Dihcl
24. Mfcd07366507
25. Xyzal Allergy 24hr
26. Xyzal (tn)
27. Levocetirizinedihydrochloride
28. Schembl144375
29. Chembl1201190
30. Levocetirizine Hydrochloride,(s)
31. Dtxsid30926567
32. Bcp21544
33. Ac-549
34. Levocetirizine Dihydrochloride (usp)
35. S4849
36. Akos015994681
37. Ccg-269359
38. Cs-w011557
39. Hy-w010841
40. Ks-1177
41. Nsc 758898
42. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid 2hcl
43. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
44. Levocetirizine Hydrochloride [mart.]
45. L0264
46. Levocetirizine Dihydrochloride [vandf]
47. Levocetirizine(r)-cetirizine (hydrochloride)
48. D08118
49. Levocetirizine Dihydrochloride [usp-rs]
50. Levocetirizine Dihydrochloride [who-dd]
51. Levocetirizine Dihydrochloride, >=98% (hplc)
52. Cetirizine (r)-form Dihydrochloride [mi]
53. 018l870
54. Levocetirizine Dihydrochloride [orange Book]
55. Levocetirizine Dihydrochloride [usp Monograph]
56. Q27289313
57. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid Dihydrochloride
Molecular Weight | 461.8 g/mol |
---|---|
Molecular Formula | C21H27Cl3N2O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 8 |
Exact Mass | 460.108726 g/mol |
Monoisotopic Mass | 460.108726 g/mol |
Topological Polar Surface Area | 53 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 443 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
2 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
3 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
4 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34731
Submission : 2020-05-12
Status : Active
Type : II
Registration Number : 302MF10110
Registrant's Address : Flat No. 302, Bhanu Enclave, Sunder Nagar, Erragadda, Hyderabad - 500038, Telangana, India
Initial Date of Registration : 2020-09-14
Latest Date of Registration : --
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-008
Start Marketing Date : 2020-03-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-17
Pay. Date : 2013-08-07
DMF Number : 21417
Submission : 2008-03-11
Status : Active
Type : II
Date of Issue : 2022-07-07
Valid Till : 2025-07-21
Written Confirmation Number : WC-0150
Address of the Firm :
NDC Package Code : 17511-106
Start Marketing Date : 2020-01-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Klasia Co., Ltd.
Registration Date : 2022-06-03
Registration Number : 20110429-40-C-279-18(2)
Manufacturer Name : Cohance Lifesciences Limited
Manufacturer Address : RS No.50/1, Mukteswarapuram Village, Jaggaiahpet Mandal, NTR District-521 457, Andhra Pradesh, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035a
Address of the Firm :
NDC Package Code : 55111-045
Start Marketing Date : 2013-10-09
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?